Oncology CER Needs Common Language, Data Collection Standards
Several articles in a comparative effectiveness research-themed issue of the Journal of Clinical Oncology highlight the need for CER to use common language and data collection standards to boost the value and usefulness of the research.
You may also be interested in...
While health technology assessment’s role primarily is to aid clinical and policy decision-making, it also has the potential to help prioritize the comparative effectiveness research agenda as well as inform trial designs, according to a recent article in the Journal of Clinical Oncology.
Researchers looking to use electronic health records may have to wait a bit longer before EHRs become a viable tool for comparative effectiveness research, based on disparities in the location of EHR adoption. A GAO report finds the highest adoption of EHRs in the South and in urban areas.
A subtle takeaway from the Oncologic Drugs Advisory Committee’s March 20 review of GlaxoSmithKline’s Votrient (pazopanib) for treatment of advanced soft tissue sarcoma was that accelerated approval, with a post-marketing requirement to confirm clinical benefit in a difficult-to-treat population, could incentivize sponsors to develop instruments for assessing symptom improvement.